NO992369L - Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus - Google Patents

Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus

Info

Publication number
NO992369L
NO992369L NO992369A NO992369A NO992369L NO 992369 L NO992369 L NO 992369L NO 992369 A NO992369 A NO 992369A NO 992369 A NO992369 A NO 992369A NO 992369 L NO992369 L NO 992369L
Authority
NO
Norway
Prior art keywords
fiv
recombinants
sub
dna
challenge
Prior art date
Application number
NO992369A
Other languages
English (en)
Other versions
NO992369D0 (no
Inventor
James Tartaglia
Enzo Paoletti
Original Assignee
Virogenetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25001826&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO992369(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Virogenetics Corp filed Critical Virogenetics Corp
Publication of NO992369D0 publication Critical patent/NO992369D0/no
Publication of NO992369L publication Critical patent/NO992369L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO992369A 1996-11-14 1999-05-14 Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus NO992369L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/746,668 US7255862B1 (en) 1996-11-14 1996-11-14 ALVAC/FIV constructs
PCT/US1997/020430 WO1998021354A1 (en) 1996-11-14 1997-11-07 Poxvirus-based expression vectors containing heterologous inserts derived from lentiviruses

Publications (2)

Publication Number Publication Date
NO992369D0 NO992369D0 (no) 1999-05-14
NO992369L true NO992369L (no) 1999-07-06

Family

ID=25001826

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992369A NO992369L (no) 1996-11-14 1999-05-14 Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus

Country Status (12)

Country Link
US (1) US7255862B1 (no)
EP (1) EP0956360B1 (no)
JP (3) JP4064466B2 (no)
AT (1) ATE330023T1 (no)
AU (1) AU733079B2 (no)
CA (1) CA2271955C (no)
DE (1) DE69736126T2 (no)
DK (1) DK0956360T3 (no)
ES (1) ES2267154T3 (no)
NO (1) NO992369L (no)
PT (1) PT956360E (no)
WO (1) WO1998021354A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7255862B1 (en) * 1996-11-14 2007-08-14 Connaught Technology Corporation ALVAC/FIV constructs
GB2356200B (en) * 1997-12-22 2002-05-01 Oxford Biomedica Ltd Retroviral vectors
EP1074625A3 (en) * 1999-06-14 2002-01-02 Pfizer Products Inc. DNA vaccine against feline immunodeficiency virus
US6541458B1 (en) 1999-07-16 2003-04-01 Merial Feline calicivirus genes and vaccines in particular recombinant vaccines
FR2796396A1 (fr) * 1999-07-16 2001-01-19 Merial Sas Gene de calicivirus felin et vaccin recombine les incorporant
FR2796397B1 (fr) * 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
DK1227837T3 (da) * 1999-10-22 2008-09-15 Aventis Pasteur Fremgangsmåde til introduktion og/eller fremskyndelse af et immunrespons på et tumorantigen
WO2001085932A2 (en) * 2000-05-10 2001-11-15 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
CA2419822C (en) * 2000-08-14 2011-02-08 Gary J. Nabel Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
CU23235A1 (es) 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
FR2825280B1 (fr) * 2001-06-01 2005-04-15 Merial Sas Vaccination contre le virus de l'immunodeficience feline
AU2003278036B2 (en) * 2002-10-22 2009-12-10 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
US20060257416A1 (en) * 2003-06-13 2006-11-16 Palmowski J M Materials and methods for improved vaccination
WO2007136763A2 (en) * 2006-05-19 2007-11-29 Sanofi Pasteur, Inc. Immunological composition
GB2460694A (en) * 2008-06-06 2009-12-09 Secr Defence Attenuated poxviruses
EP2424999A1 (en) 2009-04-30 2012-03-07 Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) Modified immunization vectors
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
EP3268044A2 (en) 2015-03-11 2018-01-17 The Broad Institute Inc. Prmt5 inhibitors for the treatment of cancer with reduced mtap activty
TWI806815B (zh) 2015-05-20 2023-07-01 美商博德研究所有限公司 共有之ｇａｔａ３相關之腫瘤特異性新抗原
US20190346442A1 (en) 2016-04-18 2019-11-14 The Broad Institute, Inc. Improved hla epitope prediction
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN110809716B (zh) 2017-02-12 2023-07-07 百欧恩泰美国公司 基于hla的方法和组合物及其用途
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
MX2021007556A (es) 2018-12-21 2021-09-10 Biontech Us Inc Método y sistemas de predicción de epítopos específicos de hla de clase ii y caracterización de células t cd4+.
AU2021280261A1 (en) 2020-05-26 2023-01-19 Dionis Therapeutics, Inc. Nucleic acid artificial mini-proteome libraries
JP2024501482A (ja) 2020-12-14 2024-01-12 ビオンテック ユーエス インコーポレイテッド がん免疫療法のための組織特異的抗原
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341439C (en) 1987-08-26 2003-09-23 Niels C. Pedersen Feline t-lymphotropic lentivirus
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5766598A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5413927A (en) 1991-09-03 1995-05-09 North Carolina State University Feline immunodeficiency virus isolate NCSU1Lb
US5736378A (en) * 1991-09-12 1998-04-07 The Scripps Research Institute Molecular cloning and characterization of the feline immunodeficiency virus isolate PPR
EP1679377A1 (en) 1994-04-29 2006-07-12 Pharmacia & Upjohn Company LLC Feline immunodeficiency virus vaccine
US7255862B1 (en) * 1996-11-14 2007-08-14 Connaught Technology Corporation ALVAC/FIV constructs

Also Published As

Publication number Publication date
US7255862B1 (en) 2007-08-14
EP0956360A4 (en) 2003-04-23
PT956360E (pt) 2006-11-30
EP0956360A1 (en) 1999-11-17
CA2271955C (en) 2010-08-17
EP0956360B1 (en) 2006-06-14
ATE330023T1 (de) 2006-07-15
JP2007001990A (ja) 2007-01-11
CA2271955A1 (en) 1998-05-22
JP2000509999A (ja) 2000-08-08
JP2003310286A (ja) 2003-11-05
WO1998021354A1 (en) 1998-05-22
JP3936303B2 (ja) 2007-06-27
DK0956360T3 (da) 2006-10-02
AU5174598A (en) 1998-06-03
JP4064466B2 (ja) 2008-03-19
DE69736126T2 (de) 2007-01-04
NO992369D0 (no) 1999-05-14
AU733079B2 (en) 2001-05-03
DE69736126D1 (de) 2006-07-27
ES2267154T3 (es) 2007-03-01

Similar Documents

Publication Publication Date Title
NO992369D0 (no) Poxvirusbaserte ekspresjonsvektorer inneholdende heterologe innslag avledet fra lentivirus
Barnett et al. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant
Barouch et al. Reduction of simian-human immunodeficiency virus 89.6 P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination
DE69535757D1 (de) Rekombinanter immunschwächepoxvirus
Bhardwaj et al. Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus
Doria-Rose et al. Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89. 6P mucosal challenge
Lema et al. HIV vaccines: A brief overview
Voss et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine
WO2004050856A3 (en) Polyvalent, primary hiv-1 glycoprotein dna vaccines and vaccination methods
US8916174B2 (en) HIV DNA vaccine regulated by a caev-derived promoter
Knudsen et al. Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen
BR0206823A (pt) Gene quimérico, proteìna quimérica, vìrus recombinante, composição de vacina, uso de uma composição de vacina, combinação terapêutica ou preventiva, e, plasmìdeo
GARDNER Vaccination against SIV infection and disease
US8765140B2 (en) DNA vaccine compositions with HIV/SIV gene modifications
Musich et al. New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design
Pahar et al. Single epitope mucosal vaccine delivered via immuno-stimulating complexes induces low level of immunity against simian-HIV
DE60238773D1 (de) Igf-1 als impfstoffhilfsmittel für katzen, insbesondere gegen feline retroviren
WO2007143606A3 (en) Hiv-1 clade a consensus sequences, antigens, and transgenes
Mealey et al. Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen
PL365742A1 (en) Vaccination against the feline immunodeficiency virus
Huisman FIV vaccine development: a continuing challenge
Tellier Immunogenicity and protective efficacy evaluation of canarypoxvirus (ALVAC)-based FIV vaccines in cats
Zhou Expression and immunogenicity of DNA vaccines containing the env and gag-pol genes of equine infectious anemia virus